Printer Friendly

Progentec concludes series A funding round with USD 5m.

M2 EQUITYBITES-January 13, 2020-Progentec concludes series A funding round with USD 5m


Progentec, a developer of nextgen diagnostics and digital therapeutics for the management of autoimmune diseases, has announced that it has completed a USD 5 million Series A funding round led by Plains Venture Partners, the Oklahoma Seed Capital Fund and the Oklahoma Angel Capital Fund II, the company said.

Also participating are NMC Health (Abu Dhabi), OCA Ventures (Chicago), Stanford University (Stanford), the Oklahoma Medical Research Foundation (Oklahoma City), Mayo Clinic, and Burns & Stowers Investments LLC (Norman, OK).

The funding round provides go-to-market capital for Progentec's CLIA laboratory and digital technologies for the management of lupus. This funding will also support new research into digital biomarkers and remote delivery of digital therapeutic programs.

Progentec is committed to improving access and health outcomes for patients in therapeutic areas with a high level of unmet need by combining clinically validated diagnostic interventions with state-of-the-art digital technologies. Through collaborations with research institutions and health practitioners around the world, Progentec is working to reduce mortality and morbidity while improving care management and service delivery for chronic health conditions.

((Comments on this story may be sent to

COPYRIGHT 2020 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2020 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Geographic Code:1U7OK
Date:Jan 13, 2020
Previous Article:First Bank appoints new chief operating officer.
Next Article:Cellect prices USD 3m in ADS.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters